title: Herpes zoster after lung transplantation: incidence, timing, and outcome.
abstract: BACKGROUND
  Although herpes zoster is a common complication of lung transplantation, the epidemiologic data are limited. The aims of the present study were to determine the incidence and clinical manifestations of herpes zoster in a large cohort of lung transplant recipients and to identify risk factors associated with its development.
  
  
  METHODS
  The files of all adult patients who underwent lung transplantation at a major tertiary medical center from January 2001 to December 2007 were reviewed. Data were extracted on background, transplant-related, and posttransplantation factors. The occurrence and clinical characteristics of all episodes of herpes zoster were recorded.
  
  
  RESULTS
  Of the 198 lung transplant recipients, 23 had a herpes zoster infection, of whom 18 had herpes in a single dermatome. Disseminated cutaneous infection was documented in 4 cases (17%) and visceral involvement in 1. The median duration of follow-up was 34 months (range, 1 to 85 months). There were no recurrent infections. Postherpetic neuralgia was detected in 26% of cases. Antiviral prophylaxis, primarily for cytomegalovirus, was effective (during treatment) against herpes zoster. The incidence of herpes zoster was higher in patients treated with rabbit antithymocyte globulin.
  
  
  CONCLUSIONS
  The occurrence of herpes zoster peaks between 12 and 36 months after lung transplantation. Additional immunosuppression may increase the risk. Further studies on preventive strategies against herpes zoster in this population are warranted.
authors.affiliation: Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.
authors.forename: Leonardo
authors.initials: L
authors.lastname: Fuks
authors.forename: David
authors.initials: D
authors.lastname: Shitrit
authors.forename: Benjamin D
authors.initials: BD
authors.lastname: Fox
authors.forename: Anat
authors.initials: A
authors.lastname: Amital
authors.forename: Yael
authors.initials: Y
authors.lastname: Raviv
authors.forename: Ilana
authors.initials: I
authors.lastname: Bakal
authors.forename: Mordechai R
authors.initials: MR
authors.lastname: Kramer
mesh_terms: D000328:Adult; D017677:Age Distribution; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006562:Herpes Zoster / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology*; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D016040:Lung Transplantation / Q000009:adverse effects* / Q000276:immunology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D015996:Survival Rate; D013997:Time Factors; D014181:Transplantation Immunology; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents